Drug
LY3200882
LY3200882 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Withdrawn2
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed125%
active_not_recruiting125%
withdrawn250%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
A Study of LY3200882 in Participants With Solid Tumors
NCT02937272
withdrawnphase_1
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
NCT04031872
withdrawnphase_1
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
NCT04158700
completedphase_1
An Interaction Study of LY3200882 in Healthy Participants
NCT03792139
Clinical Trials (4)
Showing 4 of 4 trials
NCT02937272Phase 1
A Study of LY3200882 in Participants With Solid Tumors
NCT04031872Phase 1
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
NCT04158700Phase 1
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
NCT03792139Phase 1
An Interaction Study of LY3200882 in Healthy Participants
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4